-
Services
Featured Specialties
-
Locations
Location Type
-
Patients & Visitors
-
COVID-19
6/8/2011 — New York magazine recently named 54 physicians at Yale New Haven Hospital among the best in the New York metropolitan area in its 14th annual "Best Doctors" issue. The YNHH doctors were selected from more than 6,000 physicians in the greater New York area. Forty-nine of the physicians are members of the Yale Medical Group.
Spanning 63 specialties, these are the physicians that physicians recommend. Castle Connolly Medical Ltd., a research and information company sends nomination forms to 12,000 physicians in New York City, Westchester County, Long Island and portions of New Jersey and Connecticut. Castle Connolly asks them to take into account professional qualifications, such as education, residency, board certification, reputation, etc., and patient care skills, such as listening and communication, empathy and instilling trust and confidence.
After tabulating the results, Castle Connolly publishes a guidebook, Top Doctors: New York Metro Area, which includes 1,144 top-ranked doctors. New York magazine publishes a shorter version, designed to offer geographic balance for the magazine's readership and a broad specialty representation.
| Warren Andiman, MD, Pediatric Infectious Disease John Aruny, MD, Vascular and Interventional Radiology William Batsford, MD, Cardiac Electrophysiology Michael Baumgaertner, MD, Orthopedic Surgery Jean Bolognia, MD, Dermatology Andrew Bronin, MD, Dermatology Henry Cabin, MD, Cardiovascular Disease John Colberg, MD, Urology Joshua Copel, MD, Maternal and Fetal Medicine Richard Edelson, MD, Dermatology Richard Ehrenkranz, MD, Neonatal-Perinatal Medicine John Elefteriades, MD, Thoracic Surgery Sukre Emre, MD, Surgery Harris Foster, MD, Urology Alan Friedman, MD, Pediatric Cardiology David Greer, MD, Neurology Richard Gusberg, MD, Vascular Surgery Sabet Hashim, MD, Thoracic Surgery Howard Hochster, MD, Medical Oncology Silvio Inzucchi, MD, Endocrinology, Diabetes, Metabolism Walter Kernan, MD, Internal Medicine Robert King, MD, Child and Adolescent Psychiatry John Kveton, MD, Otolaryngology David Leffell, MD, Dermatology Charles Lockwood, MD, Maternal and Fetal Medicine Walter Longo, MD, Colon and Rectal Surgery Thomas Lynch, MD, Medical Oncology |
Peter Marks, MD, PhD, Hematology |
Yale New Haven Hospital (YNHH), part of Yale New Haven Health, is a nationally recognized, 1,541-bed, not-for-profit hospital serving as the primary teaching hospital for the Yale School of Medicine (YSM). Founded as the fourth voluntary hospital in the U.S. in 1826, today, YNHH has two New Haven-based campuses, and also includes Yale New Haven Children's Hospital, Yale New Haven Psychiatric Hospital and Smilow Cancer Hospital. YNHH has received Magnet designation from the American Nurses Credentialing Center, the nation’s highest honor of nursing excellence. YNHH has a combined medical staff of about 4,500 university and community physicians practicing in more than 100 specialties. www.ynhh.org
9/30/2021
Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer CenterNew Haven, CT (September 30, 2021)— Margaret Gilshannon, MHA, has been appointed Deputy Director for Finance & Administration at Yale Cancer Center. Gilshannon joined Yale Cancer Center last year as Senior Director of Finance & Administration, while also leading the Integrated Business Operations for the Department of Pathology at Yale School of Medicine.
9/25/2021
Yale Cancer Center Study Demonstrates Efficacy of Risk Calculator in Treating Geriatric Patients with CancerNew Haven, CT (Sept. 25, 2021) - Yale Cancer Center researchers show using a validated risk calculator helped drive informed treatment decisions in older patients with cancer.
9/17/2021
Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung CancerNew Haven, CT - New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).
